Navigation Links
Center for Human Reproduction Receives Two New Patent Approvals on Androgen Supplementation for Women with Diminished Ovarian Reserve (DOR) Attempting to Conceive

New York, NY (PRWEB) August 14, 2013

Center for Human Reproduction (CHR), a leading fertility research and treatment center in New York City, announced approval of two patent applications regarding the therapeutic benefits and mechanisms of androgen supplementation for pregnancy chances of women with diminished ovarian reserve (DOR).

Combined, the two newly awarded patents (#8,501,718 and #8,501,719) describe the use of supplementation with androgens, such as dehydroepiandrosterone (DHEA), to restore ovarian environments deteriorated due to advanced female age (over 38 years) or premature ovarian aging (indicated by abnormally high FSH or abnormally low AMH levels for age).

The new patents follow the two previously awarded patents (#7,615,544 and #8,067,400), which describe DHEA supplementation as a means to improve various quality parameters of eggs and embryos, to shorten time to pregnancy and to improve pregnancy rates. Improving pregnancy chances for women with DOR has been a long-standing research focus at CHR, and CHR’s introduction of DHEA supplementation, almost a decade ago, truly revolutionized fertility treatments for women with DOR.

Having now discovered the mechanisms by which supplementation with DHEA or other androgens achieves all of these effects, one of the new patents (#8,501,719) describes these improvements as stemming from restoration of the ovarian environment to its youthful state with healthy androgen levels. The other (#8,501,718) identifies improvements in anti-Müllerian hormone (AMH) levels after androgen supplementation as a positive prognostic sign in the context of female fertility.

“These two new patents reflect research findings made at CHR already a few years ago,” explains Norbert Gleicher, MD, Medical Director and Chief Scientist at CHR, who is one of the inventors listed on the two patents. Dr. Gleicher continues: “We, indeed, have been clinically applying the knowledge described in these two patents for quite some time in our patients at CHR, as we no longer believe that eggs ‘age’ as women age. What ages is the ovarian environment in which the eggs mature. Low androgen levels are one manifestation of that ovarian aging. By increasing the patients’ androgen levels with DHEA, we are restoring the ovary’s androgen levels to where they should be at young ages. This is quite a departure from the long-held dogma that older women’s eggs are irreparably damaged, and their fertility prospects cannot be improved with medical intervention.”

About the Center for Human Reproduction (CHR)
Center for Human Reproduction, or CHR (, is a leading fertility research and treatment center in the United States with a worldwide reputation as a "fertility center of last resort," specializing in treatment of infertility in women with diminished ovarian reserve, including younger women with premature ovarian aging (POA) and older women with physiological ovarian aging. Dr. Gleicher is available for additional comments.

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Dr. Jeffrey Kenkel Appointed as Education Director of Department of Plastic Surgery at UT Southwestern Medical Center
2. Rock River Valley Blood Center Earns AABB Accreditation
3. Narconon Freedom Center Planning For National Recovery Month
4. Eye Care Center to Give Away Backpacks Filled With School Supplies to Children
5. Safe and Effective Rapid Opiate Detox Now Available from Las Vegas Rapid Detox Center
6. The Last Resort Recovery Center Awarded State Licensure
7. Reliv Kalogris Foundation Dedicates Nutrition Center for Impoverished Children in the Philippines
8. Semi truck Accident Victims Center Urges The Family Of A Innocent Victim In A Semi Truck Accident To Call Them For Instant Access To The Best Truck Accident Attorneys
9. Cloud Computing in Healthcare Up 30%: Appointment-Plus Shares 10 Reasons Why Healthcare Facilities, Wellness Centers Should Adopt an Online Enterprise Scheduling System
10. Community Health Center of Central Missouri Celebrates National Health Center Week
11. Migraine Treatment Centers of America to offer Omega Procedure in New San Antonio Facility
Post Your Comments:
(Date:11/25/2015)... ... ... Smiles by Stevens is pleased to announce the addition of ... patients are aware of the benefits of Botox® in the treatment of moderate facial ... discomfort, soreness, and pain as a result of Jaw Tension, TMJ (temporo-mandibular joint) disorder, ...
(Date:11/25/2015)... ... November 25, 2015 , ... Beddit® has launched a ... sleep tracking systems. The new app features a more intuitive SleepScore™ that rates sleep ... well you slept. The SleepScore is created by a proprietary algorithm. Beddit analyzes the ...
(Date:11/25/2015)... MI (PRWEB) , ... November 25, 2015 , ... In ... Presence Resurrection Medical Center (RMC) in Chicago, IL, UV Angel is evaluating the efficacy ... medical and surgical intensive care units (totaling 30 beds) from May 2014 through October ...
(Date:11/25/2015)... ... , ... Today, Mothers Against Drunk Driving (MADD) learned that the ... the first time since 2011. In 2014, there were 9,967 fatalities involving an alcohol ... National Highway Traffic Safety Administration (NHTSA), 32,675 people were killed in traffic crashes in ...
(Date:11/25/2015)... Spring, Md (PRWEB) , ... November 25, 2015 ... ... Pulmonary Hypertension Association (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible ... history of this disease. The Periwinkle Pioneers, nominated by the public, will receive ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... -- Henry Schein, Inc., the world,s largest provider of health ... animal health practitioners, will unveil at the Greater New ... Pavilion , which brings together for the first time ... help any practice or laboratory enter the digital age. ... of experts appearing at the Pavilion. --> ...
(Date:11/25/2015)... -- Allergan plc (NYSE: AGN ), a ... start-up  biotechnology company focused on the development of ... by the F-Prime Biomedical Research Initiative (FBRI), today ... collaboration to support the discovery and development of ... Obsessive Compulsive disorders (OCD). ...
(Date:11/25/2015)... , Nov. 25, 2015 /PRNewswire/ ... "Company") (NYSE: MR ), a ... medical devices worldwide, today announced that ... general meeting of shareholders at the ... Grand Century, 193 Prince Edward West Road, ...
Breaking Medicine Technology: